Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 4 sources
Summary
The submitted application concerns GIST after prior imatinib treatment. The pivotal comparison evaluates bezuclastinib in combination with sunitinib rather than as monotherapy. The sponsor’s expanded-access policy requires the patient to reside in the United States and requests to be submitted by the treating physician.